# Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

> **NCT01309204** · PHASE3 · COMPLETED · sponsor: **Alcon Research** · enrollment: 1184 (actual)

## Conditions studied

- Open-Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension
- **DRUG:** Vehicle
- **DRUG:** Brinzolamide 1% ophthalmic suspension
- **DRUG:** Brimonidine tartrate 0.2% ophthalmic solution

## Key facts

- **NCT ID:** NCT01309204
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 1184 (ACTUAL)
- **Last updated:** 2014-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01309204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01309204, "Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01309204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*